Download presentation
Presentation is loading. Please wait.
Published byLester Curtis Modified over 9 years ago
1
1 Impaired Decision Making In Substance Use Disorders Claire Wilcox MD UNM Dept of Psychiatry Alcohol Medical Scholars Program © AMSP
2
2 Case 55 y.o. male Physician High intelligence Methamphetamine dependent Multiple prior treatments Negative consequences: unemployed Repeated relapses Wants to quit © AMSP
3
3 This Lecture Will Cover Neurocognitive aspects Neurochemical systems Malfunction in substance use disorder (SUD) Treatment implications © AMSP
4
4 How Are Decisions Made? Mental process Neurocognitive Involves 3 stages Interconnected Experience-driven © AMSP
5
5 Stage 1: Stimulus Assessment Preference Valence Salience Context © AMSP
6
6 Stage 1: Assessment Stage 2: Execution Action selection Action performance © AMSP
7
7 Stage 3: EFFECT!! Evaluation/feedback: pros and cons of choice © AMSP
8
8 Stage 1: Assessment Stage 2: Execution Stage 3: Effect Stage 3: Learning © AMSP
9
9 Stages in the Case Stage 2 (Execution) Became obsessed Unable to fight impulse Stage 3 (Effect & Learning) Use pleasure, relief drug use reinforced Stage 1 (Assessment) Saw friend use Frustrated/stressed © AMSP
10
10 Lecture Neurocognitive aspects Neurochemical systems Malfunction in substance use disorder (SUD) Treatment implications © AMSP
11
11 Dopamine Salience Cost benefit analysis Action Inhibitory control ‘High’ Learning © AMSP Stage 1: Assessment Stage 2: Execution Stage 3: Effect & Learning
12
12 Glutamate Learning Stimulus Preference © AMSP Stage 1: Assessment Stage 2: Execution Stage 3: Learning
13
13 Noradrenaline Stress response Sympathetic NS CRF release Focus on task Exploration © AMSP Stage 1:Assessment Stage 2: Execution Stage 3: Learning
14
14 Lecture Neurocognitive aspects Neurochemical systems Malfunction in substance use disorder (SUD) Treatment implications © AMSP
15
15 Decision Making In SUDs Failure at any of 3 stages Biological root Possible pre-morbid deficits Worsened by drug use DA release to reward DA receptor density NA and CRF to stress © AMSP
16
16 Assessment Deficits Response to cue Preference,short-term reward/”high” Stress, cue salience © AMSP
17
17 Execution Deficits Habitual actions favored Can’t see other options Inhibitory control Can’t hold back © AMSP
18
18 Effect/Learning Deficits Imbalanced reward encoding First drug use, reward Once dependent o Drug reward o Further drug consumption Learning from negative © AMSP
19
19 Case Assessment: preference for drug Execution: inhibitory control Effect: / response to drug Learning: response neg consequence © AMSP
20
20 Lecture Neurocognitive aspects Neurochemical systems Malfunction in substance use disorder (SUD) Treatment implications © AMSP
21
21 Prevention Exposure Target high-risk Adolescents Genetically vulnerable Cognitive probs (schizophrenia, brain injury) Stress reactive (depressed/anxious) © AMSP
22
22 Medications Drug cue effect Naltrexone (AUDs), opioid blocker DA release Craving Relapse © AMSP
23
23 Medications Negative emotional states drug craving Methadone (opioid use disorder) Withdrawal/craving Brain stress response/ anxiety Treat co-occurring disorders © AMSP
24
24 Medications Cognitive function inhibitory control Experimental Varenicline (Nicotine Use Disorders) Memantine (Alzheimer’s Disease) © AMSP
25
25 Medications Drug reward Under development Cocaine & nicotine vaccines Abs block drug entry into brain © AMSP
26
26 Psychotherapies Contingency Management Therapy Reward changes behaviors Learn abstinence earn $$$ Relapse Prevention Therapy Identify triggers Learn avoidance © AMSP
27
27 This lecture covered Neurocognitive aspects of decision making Neurochemical systems How systems can malfunction in SUD Treatment implications © AMSP
28
28 Thanks to: Dr. Ann Manzardo (a power point genius) Dr. Marc Schuckit (for an excellent learning experience, and all of his help and time) Alcohol Medical Scholars Program (for the yummy food and spectacular hotels) © AMSP
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.